Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an expanded access protocol for use of intravenous fish oil infusion, Omegaven, in
infants and children with parenteral nutrition associated liver disease (PNALD) to decrease
elevated liver enzymes and direct bilirubin.
This study aims to describe the response of PNALD after use of Omegaven by normalization of
serum levels of liver enzymes and bilirubin.